ERBB2, erb-b2 receptor tyrosine kinase 2, 2064

N. diseases: 995; N. variants: 85
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker disease BEFREE Trastuzumab in combination with paclitaxel enhances antitumor activity by promoting apoptosis in human epidermal growth factor receptor 2-positive trastuzumab-resistant gastric cancer xenograft models. 31633500 2020
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker disease BEFREE A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy. 31667572 2020
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker disease BEFREE Notably, the addition of trastuzumab to first-line chemotherapy has improved the overall survival of patients with HER2-positive gastric cancer, and has become the standard-of-care treatment for this group of patients. 31548601 2020
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker disease BEFREE Inhibitors of CMIP could be used as potential adjuvant therapeutic drugs for HER2 positive gastric cancer. 31822364 2020
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker disease BEFREE However, the clinical significance of multi-targeting tyrosine kinase inhibitors (TKIs) in HER2-positive gastric cancer remains unclear. 31704817 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker disease BEFREE Gastric cancer (GC) has also been slow to benefit from biomarker discovery and development and the successful utilisation of targeted therapies, with the exception of trastuzumab in HER2 positive cancers. 30597479 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker disease BEFREE HER2-ECD (human epidermal growth factor receptor 2 - extracellular domain) is a prominent therapeutic target validated for treating HER2-positive breast and gastric cancer, but HER2-specific therapeutic options for treating advanced gastric cancer remain limited. 30365359 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker disease BEFREE These findings provide the basis for investigating the regulation of MAPK signaling pathways by HER2 and potential therapeutic targets for inhibiting metastasis and invasion in GC. 29734245 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker disease BEFREE Analysis of the genomic signature is not always feasible, and thus, we aimed to (i) develop and validate a practical immunohistochemistry (IHC)- and polymerase chain reaction (PCR)-based molecular classification of GC and (ii) to assess HER2 status according to this classification. 31371521 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 AlteredExpression disease BEFREE We aimed to evaluate whether HER2 expression in gastric cancer is affected by trastuzumab therapy. 30386954 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker disease BEFREE Conclusion: Evaluation of HER2/neu status in gastric cancer patients 31350955 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker disease BEFREE We analyzed 25 cases of gastric cancer that received preoperative chemotherapy and selected the six pre-treatment samples that were HER2-positive. 30348707 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 GeneticVariation disease BEFREE Bioinformatics analyses conducted on a Caucasian-based cDNA microarray databank showed Ar to be positively associated with GCa prognosis for multiple clinical modalities, including surgery, 5-Fluorouracil (5-FU) for adjuvant chemotherapy, or HER2 positivity. 31557413 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker disease BEFREE After phase III clinical trials, trastuzumab, anti-Erb-B2 receptor tyrosine kinase 2 (commonly known as ERBB2) and ramucirumab, anti-vascular endothelial growth factor receptor 2 (commonly known as VEGFR2) monoclonal antibodies, were approved and introduced into first- and second-line therapies for patients with advanced/metastatic GC. 31662821 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker disease BEFREE PD-L1 membrane expression on tumour cells (TC) and infiltrating immune cells (IC), CD3 + T-lymphocytes, CD8+ cytotoxic T-cells, ATM and HER2 were assessed by immunohistochemistry (IHC) in the ACRG (Asian Cancer Research Group) GC cohort (N = 380). 30729066 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker disease BEFREE HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany. 30826877 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker disease BEFREE Therefore, d16HER2 may be considered as a "flag" of HER2 dependence in GC and can be clinically investigated as a marker of trastuzumab susceptibility in several other HER2-driven cancers, including CRC. 30837627 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 AlteredExpression disease BEFREE Upregulation of circular RNA circ-ERBB2 predicts unfavorable prognosis and facilitates the progression of gastric cancer via miR-503/CACUL1 and miR-637/MMP-19 signaling. 30853181 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 GeneticVariation disease BEFREE Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. 30442682 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker disease BEFREE HER2 status from patients with resectable GC (UICC TNM7 tumor stage Ib-III) will be centrally determined. 31126258 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker disease BEFREE The diagnosis of HER2 positive cancer types such as breast- and gastric cancer is usually based on immunohistochemical HER2 staining of tumour tissue. 31455202 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker disease BEFREE Patients with HER2-positive GC previously treated with one line of chemotherapy received oral poziotinib (8 mg or 12 mg) once daily for 14 days, followed by 7 days off. 30945121 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker disease BEFREE With the exception of gastric cancer, there are currently no defined guidelines for HER2 testing in other digestive tumors. 31170116 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 AlteredExpression disease BEFREE The rate of human epidermal growth factor receptor 2 upregulation in patients with GC was 13.33% and it was associated with nerve invasion (χ<sup>2</sup>=4.005, P=0.045) and TNM stages III/IV (χ<sup>2</sup>=5.600, P=0.018). 31620201 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker disease BEFREE Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. 30269082 2019